Any Place for Immunohistochemistry within the Predictive Biomarkers of Treatment in Lung Cancer Patients

摘要: The identification of certain genomic alterations (EGFR, ALK, ROS1, BRAF) or immunological markers (PD-L1) in tissues cells has led to targeted treatment for patients presenting with late stage metastatic lung cancer. These biomarkers can be detected by immunohistochemistry (IHC) and/or molecular biology (MB) techniques. approaches are often complementary but depending on, the quantity and quality biological material, urgency get results, access technological platforms, financial resources expertise team, choice approach questioned. possibility detecting simultaneously several targets, analyzing degree tumor mutation burden micro-satellite instability, as well recent requirement quantify expression PD-L1 cells, case development algorithms international recommendations, which depend on samples. This review will highlight different predictive IHC cancer present advantages limitations this approach. A number perspectives considered.